Ex-imitrex, APAT grew by 88%. On the back of strong operating performance, the broking house has revised its base business earnings for FY10E and FY11E by ...
Minus the exclusivity sales of Imitrex that helped prop up revenues last year, the company recorded a decent 17 per cent growth in overall revenues during ...
We currently have a buy rating on the stock, with 15-month target price of Rs1,155, indicating an upside potential of 31%. Piramal Healthcare (PHL) is ...
